Table 1 Clinical and epidemiologic... | American Society of Hematology

Table 1

Clinical and epidemiologic characteristics of HCQ-treated patients

Parameter	HCQ patients (n = 20)*
Age, y	49.78 ± 2.92 (28-68)
Sex (male/female)	14/6
HIV infection	5.33 ± 1.38 (1-15)
Duration of ART, y	4.43 ± 1.22 (1-15)
Viral load, copies HIV RNA/mL*
Baseline	< 37
6 mo of HCQ	< 37
2 mo after HCQ interruption	< 37
Coinfections, n (%)
HBV	1/20 (5)
HCV	4/20 (20)
CD4⁺ T-cell count nadir, cells/mm³	54.57 ± 11.43 (6-112)
CD4⁺ T cells, %	10.68 ± 1.07 (3.8-18.2)
CD4⁺ T-cell counts, cells/mm³	143.70 ± 13.19 (6-200)
Total lymphocyte count, mean ± SE, cells/mm³*
Baseline	1403.33 ± 171.07
6 mo of HCQ	1338.33 ± 145.25
2 mo after HCQ interruption	1304.45 ± 149.65
ART treatment, n
PI	10
NNRTI	7
Other	3

Parameter	HCQ patients (n = 20)*
Age, y	49.78 ± 2.92 (28-68)
Sex (male/female)	14/6
HIV infection	5.33 ± 1.38 (1-15)
Duration of ART, y	4.43 ± 1.22 (1-15)
Viral load, copies HIV RNA/mL*
Baseline	< 37
6 mo of HCQ	< 37
2 mo after HCQ interruption	< 37
Coinfections, n (%)
HBV	1/20 (5)
HCV	4/20 (20)
CD4⁺ T-cell count nadir, cells/mm³	54.57 ± 11.43 (6-112)
CD4⁺ T cells, %	10.68 ± 1.07 (3.8-18.2)
CD4⁺ T-cell counts, cells/mm³	143.70 ± 13.19 (6-200)
Total lymphocyte count, mean ± SE, cells/mm³*
Baseline	1403.33 ± 171.07
6 mo of HCQ	1338.33 ± 145.25
2 mo after HCQ interruption	1304.45 ± 149.65
ART treatment, n
PI	10
NNRTI	7
Other	3

Data are presented as mean ± SE (range) except where noted.

HBV indicates hepatitis B virus; HCV, hepatitis C virus; NNRTI, nonnucleoside reverse transcriptase inhibitor; and PI, protease inhibitor

No significant differences were detected.